Cargando…
A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation
BACKGROUND: The purpose of this study was to test the efficacy and safety of daclizumab (DZM) versus anti-thymocyte globulin (ATG) as a component of induction therapy in heart transplant recipients. METHODS: Thirty heart transplant patients were randomized to receive either ATG or DZM during inducti...
Autores principales: | Mullen, John C, Kuurstra, Emily J, Oreopoulos, Antigone, Bentley, Michael J, Wang, Shaohua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120716/ https://www.ncbi.nlm.nih.gov/pubmed/25093077 http://dx.doi.org/10.1186/2047-1440-3-14 |
Ejemplares similares
-
Induction of procalcitonin in liver transplant patients treated with anti-thymocyte globulin
por: Zazula, Roman, et al.
Publicado: (2007) -
Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
por: Baron, Frédéric, et al.
Publicado: (2020) -
Comparison of Basiliximab and Anti‐Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis
por: Ansari, David, et al.
Publicado: (2015) -
Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage
por: Malvezzi, Paolo, et al.
Publicado: (2015) -
Complications of rabbit anti-thymocyte globulin induction immunosuppression in HIV-infected kidney transplant recipients
por: Al Jurdi, Ayman, et al.
Publicado: (2022)